The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Manufacturing (20 - 21) Manufacture of chemicals and pharmaceuticals 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
300 jobs Number of planned job creations
Announcement Date
29 September 2006
Employment effect (start)
1 December 2006
Foreseen end date
1 January 2009
Description
The British medical laboratory Glaxo Smith Kline (GSK) announced on 29 September 2006 that it is going to invest 500 million euro to increase its factory in Saint Amand les Eaux, in the north of France. The site, currently employing 125 people, will produce 'Cervarix' only, the future vaccine of GSK for the prevention of the cervix cancer. 300 new jobs are expected to be created between December 2006 and December 2009. The group also announced that it might create 300 additional jobs before 2011 if the new vaccine is successful. GSK employs 100,000 people in the world and 5,600 in France.
Sources
2 October 2006: Les Echos
2 October 2006: Le Figaro
29 September 2006: AFP
3 October 2006: Le Monde
Citation
Eurofound (2006), Glaxo Smith Kline, Business expansion in France, factsheet number 64168, European Restructuring Monitor. Dublin, https://apps.eurofound.europa.eu/restructuring-events/detail/64168.